Regulatory & Reimbursement
FDA Output, February 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in February 2026. Updated February 10.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Business Strategies
Healthcare Data is Driving Medtech Strategy: What Dealmakers Need to Know
Access to data and the use of it are increasingly important components of corporate strategy. How it is valued, structured and owned differentiates companies and raises challenges in dealmaking. A panel organized this month by Medtech Strategist for Weill Cornell Medicine’s BioVenture eLab Accelerator sought clarity, and an innovative, focused venture capitalist separately gives her firm’s creative investment thesis.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Business Strategies
PFA Jolts the EP Market
Pulsed field ablation is set to supplant radiofrequency and cryoablation as the preferred catheter-based approach to stopping arrhythmias. Because it is safer and faster than older technologies, it is helping electrophysiologists treat more patients and accelerate the overall growth of the cardiac ablation business. Excerpted from our recent feature, "PFA Is Ready to Electrify the Electrophysiology Market."